IRVINE, Calif., Feb. 13, 2015 /PRNewswire/ -- AtheroNova
Inc. (OTCQB: AHRO) today announced that it has received a Notice of
Issuance of Patent No. 8952067 titled "Subcutaneous Fat Reduction"
by the United States Patent and Trade Office with an expiration
date of June 20, 2032.
About AtheroNova
AtheroNova Inc. is a clinical-stage
biopharmaceutical company focused on the discovery, development,
commercialization and licensing of novel prescription compounds and
products. For more information, please visit
www.AtheroNova.com.
Forward-Looking Statements
This news release includes
"forward-looking statements." These statements are based upon the
current beliefs and expectations of AtheroNova's management and are
subject to significant risks and uncertainties. If underlying
assumptions prove inaccurate or risks or uncertainties materialize,
actual results may differ materially from those set forth in the
forward-looking statements.
Risks and uncertainties include but are not limited to, general
industry conditions and competition; significant fluctuations in
expenses associated with clinical trials, failure to secure
additional financing, the inability to complete regulatory filings
with the FDA, general economic factors, including interest rate and
currency exchange rate fluctuations; the impact of pharmaceutical
industry regulation and health care legislation in the United States and internationally; global
trends toward health care cost containment; technological advances,
new products and patents attained by competitors; challenges
inherent in new product development, including obtaining regulatory
approval; AtheroNova's ability to accurately predict future market
conditions; manufacturing difficulties or delays; financial
instability of international economies and sovereign risk;
dependence on the effectiveness of AtheroNova's patents and other
protections for innovative products; and the exposure to
litigation, including patent litigation, and/or regulatory
actions. Examples of forward-looking statements in this
release include statements regarding the potential commercial value
of any issued patents.
AtheroNova undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise. Additional factors that could cause
results to differ materially from those described in the
forward-looking statements can be found in AtheroNova's 2013 Annual
Report on Form 10-K and the company's other filings with the
Securities and Exchange Commission (SEC) available at the SEC's
Internet site (www.sec.gov).
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/atheronova-receives-notice-of-issuance-of-its-3rd-us-patent-300035553.html
SOURCE AtheroNova Inc.